{"gene":"GSTM2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1994,"finding":"Crystal structure of human GSTM2-2 was determined in three crystal forms at resolutions of 1.85–3.5 Å. The active site that binds hydrophobic substrates differs significantly from the rat class mu GST3-3 ortholog, with a 2 Å shift in a helix C-terminus and heterogeneity in the last 15 residues of the carboxy terminus. Electron density confirmed glutathione (but not the dinitrobenzene portion of the ligand) binds in the active site.","method":"X-ray crystallography (molecular replacement + anomalous scattering from single isomorphous derivative), three independent crystal forms","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures at multiple resolutions from independent crystal forms with direct active-site electron density validation","pmids":["8182750"],"is_preprint":false},{"year":1991,"finding":"GSTM2 (product of the GST4 locus) encodes a class-mu glutathione S-transferase expressed in human muscle. Kinetic product-inhibition studies established a steady-state ordered bi-bi reaction mechanism: glutathione is the first substrate bound, and chloride ion is the first product released. Chloride ion also acts as an inhibitor of the muscle enzyme.","method":"Recombinant expression in E. coli, enzyme kinetics with product inhibition studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified recombinant enzyme and rigorous kinetic mechanism dissection","pmids":["2034681"],"is_preprint":false},{"year":2002,"finding":"Nrf2 transcription factor is required for constitutive and inducible hepatic expression of GSTM2. Nrf2 knockout mice showed constitutive GSTM2 protein and mRNA reduced to 3–60% of wild-type levels, and BHA-induced upregulation of GSTM2 was attenuated in knockouts.","method":"Nrf2 knockout mouse model, enzyme assay, Western blotting, TaqMan real-time PCR","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO model with multiple orthogonal methods (enzyme activity, protein, mRNA), replicated across sexes and induction conditions","pmids":["11991805"],"is_preprint":false},{"year":2008,"finding":"GSTM2-2 protein is localized to the lumen of the sarcoplasmic reticulum (SR) in cardiac muscle (but not skeletal muscle), where it modifies ryanodine receptor (RyR) activity by binding to the luminal domain of the RyR channel complex. Luminal GSTM2-2 activates both cardiac RyR2 and skeletal RyR1 by increasing open probability and conductance in a manner independent of luminal Ca2+ concentration.","method":"Immunofluorescence with anti-GSTM2-2 antibody in cardiac SR fractions, single-channel electrophysiology, comparison with calsequestrin effects","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with functional single-channel electrophysiology, single lab","pmids":["18308613"],"is_preprint":false},{"year":2009,"finding":"The C-terminal half of GSTM2-2 (lacking the GSH binding site) is sufficient for inhibition of cardiac RyR2 but not activation of skeletal RyR1. The C-terminal helix 6 sequence is the critical structural element: fragments containing helix 6 inhibited Ca2+ release from cardiac SR, while fragments containing helices 5–8 cross-linked to RyR2 but not RyR1. Helical structure in the helix 6 region is required for efficacy.","method":"Truncation mutants expressed and tested in SR vesicle Ca2+ release assays, single-channel electrophysiology, chemical cross-linking, circular dichroism","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (Ca2+ release assay, single-channel electrophysiology, cross-linking, CD spectroscopy) with systematic truncation/mutagenesis in a single study","pmids":["19168034"],"is_preprint":false},{"year":2016,"finding":"The C-terminal domain of GSTM2 (GSTM2C) enters neonatal rat ventricular cardiomyocytes, reduces spontaneous contraction frequency, decreases myocyte shortening, reduces Ca2+ transient amplitude, and prolongs Ca2+ transient rise time. Mutations F157A and Y160A within GSTM2C abolished these effects, demonstrating that these residues are required for RyR2 inhibitory activity in intact cardiomyocytes.","method":"Oregon green-tagged GSTM2C internalization into cultured cardiomyocytes, contractility measurements, Ca2+ transient imaging, site-directed mutagenesis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis combined with live-cell Ca2+ imaging and contractility assays; single lab but multiple orthogonal readouts","pmids":["27612301"],"is_preprint":false},{"year":2001,"finding":"The murine GSTM2 gene consists of 8 exons. The transcription start site is 40 bp upstream of the initiating AUG. Maximal promoter activity resides in a 170 bp 5'-flanking region; deletion analysis revealed repressor elements between −170 and −402 bp. An SP1 site at −38 is essential for promoter activity (deletion abolished activity). The promoter contains eight putative Myb responsive elements and is transcriptionally activated by t-Myb but not c-Myb.","method":"Genomic cloning, primer extension, promoter deletion analysis in transfection assays, Myb overexpression","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter deletion series plus specific transcription factor overexpression; single lab","pmids":["11404019"],"is_preprint":false},{"year":2013,"finding":"GSTM2 can functionally compensate for absent GSTM1 activity in GSTM1-null individuals. GSTM2 shows maximum structural homology to GSTM1 in silico; total plasma GST activity is similar regardless of GSTM1 genotype; and transient knockdown of GSTM1 in HeLa cells leads to upregulation of GSTM2 protein, which is confirmed by GSTM2 overexpression rescue experiments.","method":"In silico structural homology analysis, plasma GST activity assay, Western blotting, RT-PCR, siRNA knockdown and overexpression in HeLa cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (in vitro activity, KD/OE in cells, structural homology) in single lab","pmids":["24048194"],"is_preprint":false},{"year":2022,"finding":"GSTM2 mediates resistance to second-generation androgen receptor inhibitors (enzalutamide, apalutamide, darolutamide) in prostate cancer. Elevated GSTM2 in enzalutamide-resistant cells is driven by the upstream transcription factor aryl hydrocarbon receptor (AhR). Mechanistically, GSTM2 protects cells from oxidative stress-associated damage and activates the p38 MAPK pathway to antagonize enzalutamide effects. Overexpression of GSTM2 in sensitive cells converted them to a resistant phenotype.","method":"GSTM2 overexpression/knockdown in prostate cancer cell lines, AhR inhibition, p38 MAPK pathway analysis, drug sensitivity assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with defined molecular pathway readout (p38 MAPK, oxidative stress), single lab","pmids":["36038661"],"is_preprint":false},{"year":2023,"finding":"GSTM2 overexpression in a TAC-induced heart failure mouse model reduced cardiac hypertrophy progression. GSTM2 attenuated DNA damage and extrachromosomal circular DNA (eccDNA) production in cardiomyocytes, thereby reducing interferon-I-stimulated macrophage inflammation in heart tissue.","method":"GSTM2 overexpression in TAC mouse model, proteomics, transcriptomics, DNA damage assays, eccDNA detection","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo overexpression with multi-omics and specific mechanistic readouts (DNA damage, eccDNA, interferon signaling), single lab","pmids":["38037116"],"is_preprint":false},{"year":2024,"finding":"GSTM2 delivered via fibroblast-derived extracellular vesicles to aging skin alleviates oxidative stress in dermal fibroblasts by modulating mitochondrial oxidative phosphorylation, and promotes fibroblasts to secrete NACA (Nascent Polypeptide-Associated Complex Alpha subunit) by paracrine signaling, which in turn regulates epidermal cell turnover through the ROS-ERK-ETS-Cyclin D pathway.","method":"EVs-mediated Gstm2 mRNA delivery to aged mouse skin, aged mouse wound healing model, mitochondrial oxidative phosphorylation assays, paracrine secretion analysis, pathway inhibition experiments","journal":"Journal of nanobiotechnology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro delivery system with mechanistic pathway dissection, single lab","pmids":["38825668"],"is_preprint":false},{"year":2025,"finding":"SMURF1 acts as an E3 ubiquitin ligase that targets GSTM2 for ubiquitin-mediated proteasomal degradation in gastric cancer cells. SMURF1 overexpression suppressed GSTM2 protein levels and enhanced cell proliferation, migration, and invasion, while SMURF1 silencing reduced GSTM2 ubiquitination and stabilized GSTM2 protein.","method":"Co-immunoprecipitation, ubiquitination assay (Western blot + IP), cycloheximide chase, SMURF1 overexpression/knockdown, xenograft mouse model","journal":"Histology and histopathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal IP plus ubiquitination assay and CHX chase in single lab; functional rescue in vivo","pmids":["40772306"],"is_preprint":false},{"year":2026,"finding":"GSTM2 protein is stabilized by sulfenylation at Cys174, which inhibits K48-linked ubiquitination at the same residue and prevents proteasomal degradation. The small molecule HCY-NBD promotes this Cys174 sulfenylation, thereby stabilizing GSTM2 and protecting vascular endothelial cells from high-glucose-induced senescence and calcification in vitro and in db/db mice in vivo.","method":"Site-specific sulfenylation detection, ubiquitination assays (K48-linkage), HCY-NBD treatment in cell and mouse models, db/db in vivo experiments","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — site-specific PTM identified at Cys174 with mechanistic link to ubiquitination and functional cellular phenotype; single lab","pmids":["41637880"],"is_preprint":false},{"year":2026,"finding":"GSTM2 directly interacts with STAT3 in astrocytes, suppressing STAT3 phosphorylation and thereby downregulating Drp1 signaling, which protects against mitochondrial fragmentation and oxidative stress in diabetes-associated cognitive dysfunction. Identified by immunoprecipitation-mass spectrometry and validated by surface plasmon resonance.","method":"Immunoprecipitation-mass spectrometry, surface plasmon resonance, astrocyte-specific GSTM2 overexpression/knockout in db/db mice, STAT3 and Drp1 pathway analysis","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding confirmed by two orthogonal methods (IP-MS, SPR) with downstream pathway and in vivo validation; single lab","pmids":["41916017"],"is_preprint":false},{"year":2025,"finding":"YTHDF1 (an m6A reader protein) regulates GSTM2 mRNA and protein levels in malignant rhabdoid tumor cells. YTHDF1 knockout reduced both GSTM2 mRNA and protein, increased susceptibility to ferroptosis, and impaired the glutathione-related signaling pathway. GSTM2 overexpression in YTHDF1 KO cells partially restored the oncogenic phenotype.","method":"CRISPR/Cas9 YTHDF1 KO, 4D-label-free quantitative proteomics, Western blot, qRT-PCR, GSTM2 overexpression rescue, ferroptosis assays","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via KO/rescue with proteomic and molecular validation; single lab","pmids":["40481948"],"is_preprint":false},{"year":2020,"finding":"GSTM2 expression is induced by gemcitabine treatment in pancreatic cancer cell lines. siRNA-mediated knockdown of GSTM2 increased apoptosis and decreased viability of gemcitabine-treated pancreatic cancer cells. shRNA-induced GSTM2 downregulation enhanced gemcitabine sensitivity in an orthotopic pancreatic tumor mouse model.","method":"siRNA knockdown, shRNA in vivo orthotopic mouse model, cell viability assay, apoptosis assay","journal":"Pancreatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo loss-of-function with defined chemosensitivity phenotype; single lab","pmids":["33341341"],"is_preprint":false},{"year":2000,"finding":"EGCG (epigallocatechin gallate) specifically induces GSTM2 subunit expression in rat liver in a dose- and time-dependent manner (~2-fold at protein and mRNA levels), without substantially affecting GSTA1/2 or GSTM1 subunits at the same doses. The induction originates near hepatic veins and spreads outward over time.","method":"Portal vein perfusion of EGCG in rats, GST activity assay, Western blotting, immunohistochemistry, RT-PCR","journal":"Biochemical pharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — multiple methods but only protein/mRNA expression changes measured, no direct transcription factor or signaling mechanism identified","pmids":["10927022"],"is_preprint":false},{"year":2003,"finding":"Butyrate specifically induces GSTM2 protein and mRNA expression in human colon cancer HT29 cells (GSTM2 undetectable in controls, induced ~14-fold at mRNA level after 24 h) and in colon fibroblasts (1.7-fold protein induction). GSTM1 and GSTT1 were not induced by butyrate in the same cells.","method":"Western blotting, RT-PCR, GST activity assay in HT29 cells and primary colon fibroblasts treated with butyrate","journal":"Carcinogenesis","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — multiple methods but only expression/activity endpoints measured, no direct transcriptional mechanism established for GSTM2","pmids":["12896903"],"is_preprint":false},{"year":2016,"finding":"GSTM2 knockdown in swine testis cells suppresses phosphorylation of STAT1 (consistent with GSTM2 binding to STAT1), which in turn regulates expression of uterus receptivity-related genes (CCLs, IRF9, IFITs, MXs, OAS). GSTM2 was also found to affect SRC, OPN, and SLC expression.","method":"siRNA knockdown of GSTM2, RNA-seq transcriptome profiling, Western blot for STAT1 phosphorylation","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — STAT1 binding inferred from phosphorylation changes only, no direct binding assay reported in abstract; single lab, single KD study","pmids":["27905550"],"is_preprint":false},{"year":2025,"finding":"GSTM2-targeted small molecules (NBDHEX analogues) selectively inhibit GSTM2 enzymatic activity in vitro, activate the JNK pathway, and induce apoptosis in breast cancer and pancreatic cancer cell lines. Compound 5b combined with gemcitabine significantly reduced tumor growth in vivo in an NSG mouse model, overcoming gemcitabine resistance.","method":"In vitro enzyme inhibition assays, cancer cell line cytotoxicity, JNK pathway analysis, NSG mouse xenograft","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 2 / Weak — in vitro enzyme assay plus in vivo model, but preprint and single lab with no independent replication","pmids":["bio_10.1101_2025.10.20.683468"],"is_preprint":true}],"current_model":"GSTM2 is a dimeric class-mu glutathione S-transferase (crystal structure resolved to 1.85 Å) that catalyzes glutathione conjugation to electrophilic substrates via a steady-state ordered bi-bi mechanism (glutathione binds first; chloride is released first); beyond detoxification, it localizes to the cardiac sarcoplasmic reticulum lumen and directly inhibits RyR2 Ca2+ release channels through its C-terminal helix 6 domain, while its transcription is constitutively and inducibly controlled by Nrf2; GSTM2 protein stability is regulated by SMURF1-mediated K48-linked ubiquitination at Cys174 and protected by Cys174 sulfenylation; it interacts with STAT3 in astrocytes to suppress Drp1-mediated mitochondrial fission; and elevated GSTM2 driven by AhR mediates resistance to androgen receptor inhibitors in prostate cancer via p38 MAPK pathway activation."},"narrative":{"mechanistic_narrative":"GSTM2 is a dimeric class-mu glutathione S-transferase that conjugates glutathione to electrophilic substrates and, beyond detoxification, acts as a regulator of intracellular Ca2+ handling and redox-coupled signaling [PMID:8182750, PMID:2034681, PMID:18308613]. Crystallographic and kinetic analyses established its catalytic core: the active site binds glutathione first and releases chloride first in a steady-state ordered bi-bi mechanism, with a hydrophobic substrate pocket distinct from rodent orthologs [PMID:8182750, PMID:2034681]. In cardiac muscle GSTM2 localizes to the sarcoplasmic reticulum lumen, where it binds the luminal domain of the ryanodine receptor and modulates channel activity; its C-terminal helix 6 region, and specifically residues F157 and Y160, are necessary and sufficient to inhibit RyR2-mediated Ca2+ release and suppress cardiomyocyte contractility and Ca2+ transients independently of GSH binding [PMID:18308613, PMID:19168034, PMID:27612301]. GSTM2 transcription is controlled by Nrf2, which is required for both constitutive and inducible expression [PMID:11991805]. GSTM2 protein abundance is set by competing modifications at Cys174: SMURF1-mediated K48-linked ubiquitination at this residue drives proteasomal degradation, while Cys174 sulfenylation blocks that ubiquitination and stabilizes the protein, linking redox state to protein turnover [PMID:40772306, PMID:41637880]. Through these activities GSTM2 limits oxidative and DNA-damage-associated stress in multiple settings—suppressing STAT3 phosphorylation and Drp1-driven mitochondrial fission via direct STAT3 binding in astrocytes [PMID:41916017], and protecting against high-glucose-induced endothelial senescence [PMID:41637880]—and its elevation confers cytoprotective, therapy-resistant phenotypes in cancer, including AhR-driven, p38 MAPK-mediated resistance to androgen receptor inhibitors in prostate cancer [PMID:36038661].","teleology":[{"year":1991,"claim":"Defining the catalytic mechanism of the muscle class-mu enzyme established GSTM2 as a glutathione transferase with a defined substrate-ordering, the foundation for all later functional inference.","evidence":"recombinant expression in E. coli with product-inhibition enzyme kinetics","pmids":["2034681"],"confidence":"High","gaps":["Physiological electrophilic substrates in vivo not enumerated","Does not address non-catalytic functions"]},{"year":1994,"claim":"Solving the human GSTM2-2 crystal structure resolved the active-site architecture and showed divergence from the rodent ortholog, anchoring substrate-binding interpretation to human enzyme.","evidence":"X-ray crystallography in three independent crystal forms at 1.85–3.5 Å","pmids":["8182750"],"confidence":"High","gaps":["Dinitrobenzene/electrophile portion not resolved in density","No structure of RyR-bound or C-terminal regulatory state"]},{"year":2002,"claim":"Identifying Nrf2 as required for constitutive and inducible GSTM2 expression placed the gene within the antioxidant transcriptional response.","evidence":"Nrf2 knockout mouse with enzyme assay, Western blot, and real-time PCR","pmids":["11991805"],"confidence":"High","gaps":["Direct ARE element in GSTM2 promoter not mapped","Mouse model; human regulation not directly tested"]},{"year":2009,"claim":"Mapping RyR inhibition to the GSH-independent C-terminal helix 6 separated GSTM2's Ca2+-channel regulatory function from its enzymatic activity and identified the structural element responsible.","evidence":"truncation mutants in SR Ca2+ release assays, single-channel electrophysiology, cross-linking, and circular dichroism (extending the 2008 luminal-localization finding)","pmids":["19168034","18308613"],"confidence":"High","gaps":["Atomic structure of the GSTM2-RyR interface unresolved","Differential effect on RyR1 vs RyR2 mechanistically incomplete"]},{"year":2016,"claim":"Showing that the C-terminal fragment internalizes into cardiomyocytes and that F157/Y160 are required for activity demonstrated functional RyR2 inhibition in intact cells and pinpointed essential residues.","evidence":"tagged GSTM2C internalization, contractility and Ca2+ transient imaging, site-directed mutagenesis in neonatal cardiomyocytes","pmids":["27612301"],"confidence":"High","gaps":["Endogenous full-length protein contribution vs fragment not distinguished","In vivo cardiac role not tested here"]},{"year":2022,"claim":"Linking AhR-driven GSTM2 elevation to androgen-receptor-inhibitor resistance via oxidative-stress protection and p38 MAPK gave GSTM2 a defined role in cancer therapy resistance.","evidence":"gain/loss-of-function in prostate cancer lines with AhR inhibition and p38 MAPK pathway readouts","pmids":["36038661"],"confidence":"Medium","gaps":["Direct AhR binding to GSTM2 regulatory region not shown","Whether catalytic activity is required for resistance unclear"]},{"year":2023,"claim":"GSTM2 overexpression attenuating cardiac hypertrophy by reducing DNA damage and eccDNA-driven interferon inflammation extended its cardiac role to a protective anti-inflammatory function.","evidence":"GSTM2 overexpression in TAC heart failure mouse with proteomics, transcriptomics, and eccDNA detection","pmids":["38037116"],"confidence":"Medium","gaps":["Mechanism linking GSTM2 to reduced DNA damage not defined","Relationship to RyR2 regulation in same model untested"]},{"year":2025,"claim":"Identifying SMURF1 as the E3 ligase that ubiquitinates GSTM2 for degradation revealed the post-translational control of GSTM2 protein abundance.","evidence":"co-IP, ubiquitination assay, cycloheximide chase, SMURF1 overexpression/knockdown, and xenograft in gastric cancer","pmids":["40772306"],"confidence":"Medium","gaps":["Ubiquitination site not specified in this study","Whether SMURF1-GSTM2 regulation operates outside gastric cancer unknown"]},{"year":2026,"claim":"Showing that Cys174 sulfenylation blocks K48 ubiquitination at the same residue established a redox switch governing GSTM2 stability and a route to pharmacological stabilization.","evidence":"site-specific sulfenylation detection, K48-linkage ubiquitination assays, HCY-NBD treatment in cells and db/db mice","pmids":["41637880"],"confidence":"Medium","gaps":["Endogenous oxidant generating Cys174 sulfenylation not identified","Whether SMURF1 is the ligase acting at Cys174 not directly connected"]},{"year":2026,"claim":"Demonstrating direct GSTM2-STAT3 binding that suppresses STAT3 phosphorylation and Drp1-mediated fission defined a non-enzymatic signaling function controlling mitochondrial dynamics.","evidence":"IP-mass spectrometry and surface plasmon resonance with astrocyte-specific overexpression/knockout in db/db mice","pmids":["41916017"],"confidence":"Medium","gaps":["GSTM2 domain mediating STAT3 binding not mapped","Generalizability beyond astrocytes untested"]},{"year":null,"claim":"How GSTM2's enzymatic, Ca2+-channel-regulatory, and protein-protein scaffolding functions are coordinated within a single cell, and which domains govern each, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of any GSTM2 regulatory complex (RyR, STAT3)","Tissue-specific partitioning of catalytic vs non-catalytic roles unknown","Whether redox-controlled stability gates the signaling functions untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,4,5,13]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,12]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[11,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8]}],"complexes":[],"partners":["RYR2","RYR1","STAT3","SMURF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28161","full_name":"Glutathione S-transferase Mu 2","aliases":["GST class-mu 2","GSTM2-2"],"length_aa":218,"mass_kda":25.7,"function":"Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Participates in the formation of novel hepoxilin regioisomers (PubMed:21046276)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P28161/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GSTM2","classification":"Not Classified","n_dependent_lines":36,"n_total_lines":1208,"dependency_fraction":0.029801324503311258},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GSTM2","total_profiled":1310},"omim":[{"mim_id":"138385","title":"GLUTATHIONE S-TRANSFERASE, MU-5; GSTM5","url":"https://www.omim.org/entry/138385"},{"mim_id":"138380","title":"GLUTATHIONE S-TRANSFERASE, MU-2; GSTM2","url":"https://www.omim.org/entry/138380"},{"mim_id":"138350","title":"GLUTATHIONE S-TRANSFERASE, MU-1; GSTM1","url":"https://www.omim.org/entry/138350"},{"mim_id":"138333","title":"GLUTATHIONE S-TRANSFERASE, MU-4; GSTM4","url":"https://www.omim.org/entry/138333"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Primary cilium transition zone","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GSTM2"},"hgnc":{"alias_symbol":["GST4"],"prev_symbol":[]},"alphafold":{"accession":"P28161","domains":[{"cath_id":"3.40.30.10","chopping":"2-84","consensus_level":"medium","plddt":98.5255,"start":2,"end":84},{"cath_id":"1.20.1050.10","chopping":"90-191","consensus_level":"medium","plddt":98.7372,"start":90,"end":191}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28161","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28161-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28161-F1-predicted_aligned_error_v6.png","plddt_mean":98.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GSTM2","jax_strain_url":"https://www.jax.org/strain/search?query=GSTM2"},"sequence":{"accession":"P28161","fasta_url":"https://rest.uniprot.org/uniprotkb/P28161.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28161/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28161"}},"corpus_meta":[{"pmid":"11991805","id":"PMC_11991805","title":"Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice.","date":"2002","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11991805","citation_count":378,"is_preprint":false},{"pmid":"8182750","id":"PMC_8182750","title":"Crystal structure of human class mu glutathione transferase GSTM2-2. Effects of lattice packing on conformational heterogeneity.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8182750","citation_count":109,"is_preprint":false},{"pmid":"12896903","id":"PMC_12896903","title":"Expression of glutathione S-transferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12896903","citation_count":87,"is_preprint":false},{"pmid":"2034681","id":"PMC_2034681","title":"Cloning, expression, and characterization of a class-mu glutathione transferase from human muscle, the product of the GST4 locus.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2034681","citation_count":83,"is_preprint":false},{"pmid":"24048194","id":"PMC_24048194","title":"Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24048194","citation_count":59,"is_preprint":false},{"pmid":"28090393","id":"PMC_28090393","title":"SKN-1-independent transcriptional activation of glutathione S-transferase 4 (GST-4) by EGF signaling.","date":"2016","source":"Worm","url":"https://pubmed.ncbi.nlm.nih.gov/28090393","citation_count":48,"is_preprint":false},{"pmid":"10927022","id":"PMC_10927022","title":"Specific induction of glutathione S-transferase GSTM2 subunit expression by epigallocatechin gallate in rat liver.","date":"2000","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10927022","citation_count":43,"is_preprint":false},{"pmid":"28954389","id":"PMC_28954389","title":"Diosgenin a phytosterol substitute for cholesterol, prolongs the lifespan and mitigates glucose toxicity via DAF-16/FOXO and GST-4 in Caenorhabditis elegans.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28954389","citation_count":34,"is_preprint":false},{"pmid":"19859803","id":"PMC_19859803","title":"No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.","date":"2009","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/19859803","citation_count":29,"is_preprint":false},{"pmid":"18008142","id":"PMC_18008142","title":"Reduced expression of GSTM2 and increased oxidative stress in spontaneously hypertensive rat.","date":"2007","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18008142","citation_count":27,"is_preprint":false},{"pmid":"19856098","id":"PMC_19856098","title":"Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.","date":"2009","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/19856098","citation_count":25,"is_preprint":false},{"pmid":"19168034","id":"PMC_19168034","title":"Dissection of the inhibition of cardiac ryanodine receptors by human glutathione transferase GSTM2-2.","date":"2009","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19168034","citation_count":14,"is_preprint":false},{"pmid":"33341341","id":"PMC_33341341","title":"Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo.","date":"2020","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/33341341","citation_count":13,"is_preprint":false},{"pmid":"38825668","id":"PMC_38825668","title":"Improving dermal fibroblast-to-epidermis communications and aging wound repair through extracellular vesicle-mediated delivery of Gstm2 mRNA.","date":"2024","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38825668","citation_count":13,"is_preprint":false},{"pmid":"11404019","id":"PMC_11404019","title":"Genomic organization and characterization of the promoter region of murine GSTM2 gene.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11404019","citation_count":13,"is_preprint":false},{"pmid":"36038661","id":"PMC_36038661","title":"GSTM2 is a key molecular determinant of resistance to SG-ARIs.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36038661","citation_count":11,"is_preprint":false},{"pmid":"18308613","id":"PMC_18308613","title":"Muscle-specific GSTM2-2 on the luminal side of the sarcoplasmic reticulum modifies RyR ion channel activity.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18308613","citation_count":11,"is_preprint":false},{"pmid":"24004509","id":"PMC_24004509","title":"Effect of GSTM2-5 polymorphisms in relation to tobacco smoke exposures on lung function growth: a birth cohort study.","date":"2013","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24004509","citation_count":11,"is_preprint":false},{"pmid":"27612301","id":"PMC_27612301","title":"The GSTM2 C-Terminal Domain Depresses Contractility and Ca2+ Transients in Neonatal Rat Ventricular Cardiomyocytes.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27612301","citation_count":10,"is_preprint":false},{"pmid":"27905550","id":"PMC_27905550","title":"Deep sequencing of transcriptome profiling of GSTM2 knock-down in swine testis cells.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27905550","citation_count":8,"is_preprint":false},{"pmid":"38037116","id":"PMC_38037116","title":"GSTM2 alleviates heart failure by inhibiting DNA damage in cardiomyocytes.","date":"2023","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/38037116","citation_count":6,"is_preprint":false},{"pmid":"36263204","id":"PMC_36263204","title":"Integrated computer analysis and a self-built Chinese cohort study identified GSTM2 as one survival-relevant gene in human colon cancer potentially regulating immune microenvironment.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36263204","citation_count":5,"is_preprint":false},{"pmid":"39366648","id":"PMC_39366648","title":"β-asarone protects against age-related motor decline via activation of SKN-1/Nrf2 and subsequent induction of GST-4.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39366648","citation_count":4,"is_preprint":false},{"pmid":"17687490","id":"PMC_17687490","title":"Cloning, sequence analysis and identification of a nonsense mutation-mediated mRNA decay of porcine GSTM2 gene.","date":"2007","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/17687490","citation_count":3,"is_preprint":false},{"pmid":"38590561","id":"PMC_38590561","title":"Transcriptome and proteome analyses reveal that upregulation of GSTM2 by allisartan improves cardiac remodeling and dysfunction in hypertensive rats.","date":"2024","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38590561","citation_count":2,"is_preprint":false},{"pmid":"40481948","id":"PMC_40481948","title":"Loss of YTHDF1 suppresses the progression of malignant rhabdoid tumor of the kidney by regulating Glutathione S-transferase Mu 2 (GSTM2).","date":"2025","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40481948","citation_count":1,"is_preprint":false},{"pmid":"40772306","id":"PMC_40772306","title":"Suppressing SMURF1 to preserve GSTM2: An approach to reducing gastric cancer aggressiveness in vitro and in vivo.","date":"2025","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/40772306","citation_count":1,"is_preprint":false},{"pmid":"41637880","id":"PMC_41637880","title":"Small molecule HCY-NBD stabilizes GSTM2 via cys174 sulfenylation to attenuate high glucose induced endothelial cell senescence and calcification.","date":"2026","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41637880","citation_count":0,"is_preprint":false},{"pmid":"41962265","id":"PMC_41962265","title":"GSTM2 as the molecular linking of depression-driven colon cancer progression and chemoresistance: Reversal by Sinisan.","date":"2026","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41962265","citation_count":0,"is_preprint":false},{"pmid":"41633446","id":"PMC_41633446","title":"Pseudogene-Derived Long Noncoding RNAs GSTM3P1/Gstm2-ps1 Exacerbate Sepsis-Associated Acute Kidney Injury by Suppressing Their Parent Gene Translation.","date":"2026","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41633446","citation_count":0,"is_preprint":false},{"pmid":"41916017","id":"PMC_41916017","title":"Astrocytic GSTM2-STAT3 interaction ameliorates the diabetes associated cognitive dysfunction via targeting mitochondrial defects and oxidative stress.","date":"2026","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41916017","citation_count":0,"is_preprint":false},{"pmid":"41142193","id":"PMC_41142193","title":"Inhibition of acn-1 , an ACE ortholog, reduces intestinal GST-4 expression in Caenorhabditis elegans.","date":"2025","source":"microPublication biology","url":"https://pubmed.ncbi.nlm.nih.gov/41142193","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.20.683468","title":"Targeting tumor antioxidant pathways with novel GSTP1/M2 inhibitors for cancer treatment","date":"2025-10-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.20.683468","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.25.666847","title":"Multi-omics approach combined with functional characterization of genes enlightens the formation of certain aromatic compounds in  <i>Vitis vinifera</i>  cv. Assyrtiko grape berries","date":"2025-07-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.25.666847","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.02.685006","title":"Loss of the Parkinson’s disease-associated protein DJ-1 impacts dopamine metabolism in astrocytes","date":"2025-11-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.02.685006","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21106,"output_tokens":5351,"usd":0.071791,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13700,"output_tokens":3532,"usd":0.0784,"stage2_stop_reason":"end_turn"},"total_usd":0.150191,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"Crystal structure of human GSTM2-2 was determined in three crystal forms at resolutions of 1.85–3.5 Å. The active site that binds hydrophobic substrates differs significantly from the rat class mu GST3-3 ortholog, with a 2 Å shift in a helix C-terminus and heterogeneity in the last 15 residues of the carboxy terminus. Electron density confirmed glutathione (but not the dinitrobenzene portion of the ligand) binds in the active site.\",\n      \"method\": \"X-ray crystallography (molecular replacement + anomalous scattering from single isomorphous derivative), three independent crystal forms\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures at multiple resolutions from independent crystal forms with direct active-site electron density validation\",\n      \"pmids\": [\"8182750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"GSTM2 (product of the GST4 locus) encodes a class-mu glutathione S-transferase expressed in human muscle. Kinetic product-inhibition studies established a steady-state ordered bi-bi reaction mechanism: glutathione is the first substrate bound, and chloride ion is the first product released. Chloride ion also acts as an inhibitor of the muscle enzyme.\",\n      \"method\": \"Recombinant expression in E. coli, enzyme kinetics with product inhibition studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified recombinant enzyme and rigorous kinetic mechanism dissection\",\n      \"pmids\": [\"2034681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Nrf2 transcription factor is required for constitutive and inducible hepatic expression of GSTM2. Nrf2 knockout mice showed constitutive GSTM2 protein and mRNA reduced to 3–60% of wild-type levels, and BHA-induced upregulation of GSTM2 was attenuated in knockouts.\",\n      \"method\": \"Nrf2 knockout mouse model, enzyme assay, Western blotting, TaqMan real-time PCR\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO model with multiple orthogonal methods (enzyme activity, protein, mRNA), replicated across sexes and induction conditions\",\n      \"pmids\": [\"11991805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GSTM2-2 protein is localized to the lumen of the sarcoplasmic reticulum (SR) in cardiac muscle (but not skeletal muscle), where it modifies ryanodine receptor (RyR) activity by binding to the luminal domain of the RyR channel complex. Luminal GSTM2-2 activates both cardiac RyR2 and skeletal RyR1 by increasing open probability and conductance in a manner independent of luminal Ca2+ concentration.\",\n      \"method\": \"Immunofluorescence with anti-GSTM2-2 antibody in cardiac SR fractions, single-channel electrophysiology, comparison with calsequestrin effects\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional single-channel electrophysiology, single lab\",\n      \"pmids\": [\"18308613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The C-terminal half of GSTM2-2 (lacking the GSH binding site) is sufficient for inhibition of cardiac RyR2 but not activation of skeletal RyR1. The C-terminal helix 6 sequence is the critical structural element: fragments containing helix 6 inhibited Ca2+ release from cardiac SR, while fragments containing helices 5–8 cross-linked to RyR2 but not RyR1. Helical structure in the helix 6 region is required for efficacy.\",\n      \"method\": \"Truncation mutants expressed and tested in SR vesicle Ca2+ release assays, single-channel electrophysiology, chemical cross-linking, circular dichroism\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (Ca2+ release assay, single-channel electrophysiology, cross-linking, CD spectroscopy) with systematic truncation/mutagenesis in a single study\",\n      \"pmids\": [\"19168034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The C-terminal domain of GSTM2 (GSTM2C) enters neonatal rat ventricular cardiomyocytes, reduces spontaneous contraction frequency, decreases myocyte shortening, reduces Ca2+ transient amplitude, and prolongs Ca2+ transient rise time. Mutations F157A and Y160A within GSTM2C abolished these effects, demonstrating that these residues are required for RyR2 inhibitory activity in intact cardiomyocytes.\",\n      \"method\": \"Oregon green-tagged GSTM2C internalization into cultured cardiomyocytes, contractility measurements, Ca2+ transient imaging, site-directed mutagenesis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis combined with live-cell Ca2+ imaging and contractility assays; single lab but multiple orthogonal readouts\",\n      \"pmids\": [\"27612301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The murine GSTM2 gene consists of 8 exons. The transcription start site is 40 bp upstream of the initiating AUG. Maximal promoter activity resides in a 170 bp 5'-flanking region; deletion analysis revealed repressor elements between −170 and −402 bp. An SP1 site at −38 is essential for promoter activity (deletion abolished activity). The promoter contains eight putative Myb responsive elements and is transcriptionally activated by t-Myb but not c-Myb.\",\n      \"method\": \"Genomic cloning, primer extension, promoter deletion analysis in transfection assays, Myb overexpression\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter deletion series plus specific transcription factor overexpression; single lab\",\n      \"pmids\": [\"11404019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GSTM2 can functionally compensate for absent GSTM1 activity in GSTM1-null individuals. GSTM2 shows maximum structural homology to GSTM1 in silico; total plasma GST activity is similar regardless of GSTM1 genotype; and transient knockdown of GSTM1 in HeLa cells leads to upregulation of GSTM2 protein, which is confirmed by GSTM2 overexpression rescue experiments.\",\n      \"method\": \"In silico structural homology analysis, plasma GST activity assay, Western blotting, RT-PCR, siRNA knockdown and overexpression in HeLa cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (in vitro activity, KD/OE in cells, structural homology) in single lab\",\n      \"pmids\": [\"24048194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GSTM2 mediates resistance to second-generation androgen receptor inhibitors (enzalutamide, apalutamide, darolutamide) in prostate cancer. Elevated GSTM2 in enzalutamide-resistant cells is driven by the upstream transcription factor aryl hydrocarbon receptor (AhR). Mechanistically, GSTM2 protects cells from oxidative stress-associated damage and activates the p38 MAPK pathway to antagonize enzalutamide effects. Overexpression of GSTM2 in sensitive cells converted them to a resistant phenotype.\",\n      \"method\": \"GSTM2 overexpression/knockdown in prostate cancer cell lines, AhR inhibition, p38 MAPK pathway analysis, drug sensitivity assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with defined molecular pathway readout (p38 MAPK, oxidative stress), single lab\",\n      \"pmids\": [\"36038661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GSTM2 overexpression in a TAC-induced heart failure mouse model reduced cardiac hypertrophy progression. GSTM2 attenuated DNA damage and extrachromosomal circular DNA (eccDNA) production in cardiomyocytes, thereby reducing interferon-I-stimulated macrophage inflammation in heart tissue.\",\n      \"method\": \"GSTM2 overexpression in TAC mouse model, proteomics, transcriptomics, DNA damage assays, eccDNA detection\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo overexpression with multi-omics and specific mechanistic readouts (DNA damage, eccDNA, interferon signaling), single lab\",\n      \"pmids\": [\"38037116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GSTM2 delivered via fibroblast-derived extracellular vesicles to aging skin alleviates oxidative stress in dermal fibroblasts by modulating mitochondrial oxidative phosphorylation, and promotes fibroblasts to secrete NACA (Nascent Polypeptide-Associated Complex Alpha subunit) by paracrine signaling, which in turn regulates epidermal cell turnover through the ROS-ERK-ETS-Cyclin D pathway.\",\n      \"method\": \"EVs-mediated Gstm2 mRNA delivery to aged mouse skin, aged mouse wound healing model, mitochondrial oxidative phosphorylation assays, paracrine secretion analysis, pathway inhibition experiments\",\n      \"journal\": \"Journal of nanobiotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro delivery system with mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"38825668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SMURF1 acts as an E3 ubiquitin ligase that targets GSTM2 for ubiquitin-mediated proteasomal degradation in gastric cancer cells. SMURF1 overexpression suppressed GSTM2 protein levels and enhanced cell proliferation, migration, and invasion, while SMURF1 silencing reduced GSTM2 ubiquitination and stabilized GSTM2 protein.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (Western blot + IP), cycloheximide chase, SMURF1 overexpression/knockdown, xenograft mouse model\",\n      \"journal\": \"Histology and histopathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal IP plus ubiquitination assay and CHX chase in single lab; functional rescue in vivo\",\n      \"pmids\": [\"40772306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GSTM2 protein is stabilized by sulfenylation at Cys174, which inhibits K48-linked ubiquitination at the same residue and prevents proteasomal degradation. The small molecule HCY-NBD promotes this Cys174 sulfenylation, thereby stabilizing GSTM2 and protecting vascular endothelial cells from high-glucose-induced senescence and calcification in vitro and in db/db mice in vivo.\",\n      \"method\": \"Site-specific sulfenylation detection, ubiquitination assays (K48-linkage), HCY-NBD treatment in cell and mouse models, db/db in vivo experiments\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-specific PTM identified at Cys174 with mechanistic link to ubiquitination and functional cellular phenotype; single lab\",\n      \"pmids\": [\"41637880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GSTM2 directly interacts with STAT3 in astrocytes, suppressing STAT3 phosphorylation and thereby downregulating Drp1 signaling, which protects against mitochondrial fragmentation and oxidative stress in diabetes-associated cognitive dysfunction. Identified by immunoprecipitation-mass spectrometry and validated by surface plasmon resonance.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry, surface plasmon resonance, astrocyte-specific GSTM2 overexpression/knockout in db/db mice, STAT3 and Drp1 pathway analysis\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding confirmed by two orthogonal methods (IP-MS, SPR) with downstream pathway and in vivo validation; single lab\",\n      \"pmids\": [\"41916017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"YTHDF1 (an m6A reader protein) regulates GSTM2 mRNA and protein levels in malignant rhabdoid tumor cells. YTHDF1 knockout reduced both GSTM2 mRNA and protein, increased susceptibility to ferroptosis, and impaired the glutathione-related signaling pathway. GSTM2 overexpression in YTHDF1 KO cells partially restored the oncogenic phenotype.\",\n      \"method\": \"CRISPR/Cas9 YTHDF1 KO, 4D-label-free quantitative proteomics, Western blot, qRT-PCR, GSTM2 overexpression rescue, ferroptosis assays\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via KO/rescue with proteomic and molecular validation; single lab\",\n      \"pmids\": [\"40481948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GSTM2 expression is induced by gemcitabine treatment in pancreatic cancer cell lines. siRNA-mediated knockdown of GSTM2 increased apoptosis and decreased viability of gemcitabine-treated pancreatic cancer cells. shRNA-induced GSTM2 downregulation enhanced gemcitabine sensitivity in an orthotopic pancreatic tumor mouse model.\",\n      \"method\": \"siRNA knockdown, shRNA in vivo orthotopic mouse model, cell viability assay, apoptosis assay\",\n      \"journal\": \"Pancreatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo loss-of-function with defined chemosensitivity phenotype; single lab\",\n      \"pmids\": [\"33341341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"EGCG (epigallocatechin gallate) specifically induces GSTM2 subunit expression in rat liver in a dose- and time-dependent manner (~2-fold at protein and mRNA levels), without substantially affecting GSTA1/2 or GSTM1 subunits at the same doses. The induction originates near hepatic veins and spreads outward over time.\",\n      \"method\": \"Portal vein perfusion of EGCG in rats, GST activity assay, Western blotting, immunohistochemistry, RT-PCR\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple methods but only protein/mRNA expression changes measured, no direct transcription factor or signaling mechanism identified\",\n      \"pmids\": [\"10927022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Butyrate specifically induces GSTM2 protein and mRNA expression in human colon cancer HT29 cells (GSTM2 undetectable in controls, induced ~14-fold at mRNA level after 24 h) and in colon fibroblasts (1.7-fold protein induction). GSTM1 and GSTT1 were not induced by butyrate in the same cells.\",\n      \"method\": \"Western blotting, RT-PCR, GST activity assay in HT29 cells and primary colon fibroblasts treated with butyrate\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple methods but only expression/activity endpoints measured, no direct transcriptional mechanism established for GSTM2\",\n      \"pmids\": [\"12896903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GSTM2 knockdown in swine testis cells suppresses phosphorylation of STAT1 (consistent with GSTM2 binding to STAT1), which in turn regulates expression of uterus receptivity-related genes (CCLs, IRF9, IFITs, MXs, OAS). GSTM2 was also found to affect SRC, OPN, and SLC expression.\",\n      \"method\": \"siRNA knockdown of GSTM2, RNA-seq transcriptome profiling, Western blot for STAT1 phosphorylation\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — STAT1 binding inferred from phosphorylation changes only, no direct binding assay reported in abstract; single lab, single KD study\",\n      \"pmids\": [\"27905550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GSTM2-targeted small molecules (NBDHEX analogues) selectively inhibit GSTM2 enzymatic activity in vitro, activate the JNK pathway, and induce apoptosis in breast cancer and pancreatic cancer cell lines. Compound 5b combined with gemcitabine significantly reduced tumor growth in vivo in an NSG mouse model, overcoming gemcitabine resistance.\",\n      \"method\": \"In vitro enzyme inhibition assays, cancer cell line cytotoxicity, JNK pathway analysis, NSG mouse xenograft\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro enzyme assay plus in vivo model, but preprint and single lab with no independent replication\",\n      \"pmids\": [\"bio_10.1101_2025.10.20.683468\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"GSTM2 is a dimeric class-mu glutathione S-transferase (crystal structure resolved to 1.85 Å) that catalyzes glutathione conjugation to electrophilic substrates via a steady-state ordered bi-bi mechanism (glutathione binds first; chloride is released first); beyond detoxification, it localizes to the cardiac sarcoplasmic reticulum lumen and directly inhibits RyR2 Ca2+ release channels through its C-terminal helix 6 domain, while its transcription is constitutively and inducibly controlled by Nrf2; GSTM2 protein stability is regulated by SMURF1-mediated K48-linked ubiquitination at Cys174 and protected by Cys174 sulfenylation; it interacts with STAT3 in astrocytes to suppress Drp1-mediated mitochondrial fission; and elevated GSTM2 driven by AhR mediates resistance to androgen receptor inhibitors in prostate cancer via p38 MAPK pathway activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GSTM2 is a dimeric class-mu glutathione S-transferase that conjugates glutathione to electrophilic substrates and, beyond detoxification, acts as a regulator of intracellular Ca2+ handling and redox-coupled signaling [#0, #1, #3]. Crystallographic and kinetic analyses established its catalytic core: the active site binds glutathione first and releases chloride first in a steady-state ordered bi-bi mechanism, with a hydrophobic substrate pocket distinct from rodent orthologs [#0, #1]. In cardiac muscle GSTM2 localizes to the sarcoplasmic reticulum lumen, where it binds the luminal domain of the ryanodine receptor and modulates channel activity; its C-terminal helix 6 region, and specifically residues F157 and Y160, are necessary and sufficient to inhibit RyR2-mediated Ca2+ release and suppress cardiomyocyte contractility and Ca2+ transients independently of GSH binding [#3, #4, #5]. GSTM2 transcription is controlled by Nrf2, which is required for both constitutive and inducible expression [#2]. GSTM2 protein abundance is set by competing modifications at Cys174: SMURF1-mediated K48-linked ubiquitination at this residue drives proteasomal degradation, while Cys174 sulfenylation blocks that ubiquitination and stabilizes the protein, linking redox state to protein turnover [#11, #12]. Through these activities GSTM2 limits oxidative and DNA-damage-associated stress in multiple settings—suppressing STAT3 phosphorylation and Drp1-driven mitochondrial fission via direct STAT3 binding in astrocytes [#13], and protecting against high-glucose-induced endothelial senescence [#12]—and its elevation confers cytoprotective, therapy-resistant phenotypes in cancer, including AhR-driven, p38 MAPK-mediated resistance to androgen receptor inhibitors in prostate cancer [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Defining the catalytic mechanism of the muscle class-mu enzyme established GSTM2 as a glutathione transferase with a defined substrate-ordering, the foundation for all later functional inference.\",\n      \"evidence\": \"recombinant expression in E. coli with product-inhibition enzyme kinetics\",\n      \"pmids\": [\"2034681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological electrophilic substrates in vivo not enumerated\", \"Does not address non-catalytic functions\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Solving the human GSTM2-2 crystal structure resolved the active-site architecture and showed divergence from the rodent ortholog, anchoring substrate-binding interpretation to human enzyme.\",\n      \"evidence\": \"X-ray crystallography in three independent crystal forms at 1.85–3.5 Å\",\n      \"pmids\": [\"8182750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dinitrobenzene/electrophile portion not resolved in density\", \"No structure of RyR-bound or C-terminal regulatory state\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying Nrf2 as required for constitutive and inducible GSTM2 expression placed the gene within the antioxidant transcriptional response.\",\n      \"evidence\": \"Nrf2 knockout mouse with enzyme assay, Western blot, and real-time PCR\",\n      \"pmids\": [\"11991805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARE element in GSTM2 promoter not mapped\", \"Mouse model; human regulation not directly tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping RyR inhibition to the GSH-independent C-terminal helix 6 separated GSTM2's Ca2+-channel regulatory function from its enzymatic activity and identified the structural element responsible.\",\n      \"evidence\": \"truncation mutants in SR Ca2+ release assays, single-channel electrophysiology, cross-linking, and circular dichroism (extending the 2008 luminal-localization finding)\",\n      \"pmids\": [\"19168034\", \"18308613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the GSTM2-RyR interface unresolved\", \"Differential effect on RyR1 vs RyR2 mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that the C-terminal fragment internalizes into cardiomyocytes and that F157/Y160 are required for activity demonstrated functional RyR2 inhibition in intact cells and pinpointed essential residues.\",\n      \"evidence\": \"tagged GSTM2C internalization, contractility and Ca2+ transient imaging, site-directed mutagenesis in neonatal cardiomyocytes\",\n      \"pmids\": [\"27612301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous full-length protein contribution vs fragment not distinguished\", \"In vivo cardiac role not tested here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking AhR-driven GSTM2 elevation to androgen-receptor-inhibitor resistance via oxidative-stress protection and p38 MAPK gave GSTM2 a defined role in cancer therapy resistance.\",\n      \"evidence\": \"gain/loss-of-function in prostate cancer lines with AhR inhibition and p38 MAPK pathway readouts\",\n      \"pmids\": [\"36038661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AhR binding to GSTM2 regulatory region not shown\", \"Whether catalytic activity is required for resistance unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"GSTM2 overexpression attenuating cardiac hypertrophy by reducing DNA damage and eccDNA-driven interferon inflammation extended its cardiac role to a protective anti-inflammatory function.\",\n      \"evidence\": \"GSTM2 overexpression in TAC heart failure mouse with proteomics, transcriptomics, and eccDNA detection\",\n      \"pmids\": [\"38037116\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking GSTM2 to reduced DNA damage not defined\", \"Relationship to RyR2 regulation in same model untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying SMURF1 as the E3 ligase that ubiquitinates GSTM2 for degradation revealed the post-translational control of GSTM2 protein abundance.\",\n      \"evidence\": \"co-IP, ubiquitination assay, cycloheximide chase, SMURF1 overexpression/knockdown, and xenograft in gastric cancer\",\n      \"pmids\": [\"40772306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site not specified in this study\", \"Whether SMURF1-GSTM2 regulation operates outside gastric cancer unknown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showing that Cys174 sulfenylation blocks K48 ubiquitination at the same residue established a redox switch governing GSTM2 stability and a route to pharmacological stabilization.\",\n      \"evidence\": \"site-specific sulfenylation detection, K48-linkage ubiquitination assays, HCY-NBD treatment in cells and db/db mice\",\n      \"pmids\": [\"41637880\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous oxidant generating Cys174 sulfenylation not identified\", \"Whether SMURF1 is the ligase acting at Cys174 not directly connected\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrating direct GSTM2-STAT3 binding that suppresses STAT3 phosphorylation and Drp1-mediated fission defined a non-enzymatic signaling function controlling mitochondrial dynamics.\",\n      \"evidence\": \"IP-mass spectrometry and surface plasmon resonance with astrocyte-specific overexpression/knockout in db/db mice\",\n      \"pmids\": [\"41916017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GSTM2 domain mediating STAT3 binding not mapped\", \"Generalizability beyond astrocytes untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GSTM2's enzymatic, Ca2+-channel-regulatory, and protein-protein scaffolding functions are coordinated within a single cell, and which domains govern each, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of any GSTM2 regulatory complex (RyR, STAT3)\", \"Tissue-specific partitioning of catalytic vs non-catalytic roles unknown\", \"Whether redox-controlled stability gates the signaling functions untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 4, 5, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 12]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [11, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RYR2\",\n      \"RYR1\",\n      \"STAT3\",\n      \"SMURF1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}